Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Zolmitriptan: differences from sumatriptan.

P J Goadsby1, C J Boes

  • 1Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK. peterg@ion.ucl.ac.uk

Current Medical Research and Opinion
|December 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The evolving landscape of primary headache therapy.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same author

Same-Day Bilateral Decubitus CT Myelography for Detecting CSF-Venous Fistulas in Spontaneous Intracranial Hypotension.

AJNR. American journal of neuroradiology·2022
Same author

Visual snow syndrome: is it normal or a disorder - and what to do with patients?

European journal of neurology·2020
Same author

Visual snow syndrome: a comparison between an Italian and British population.

European journal of neurology·2020
Same author

Response to 'Do different treatment strategies of galcanezumab have similar effect on migraine?'

European journal of neurology·2020
Same author

Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials.

European journal of neurology·2019
Same journal

Multidrug-resistant <i>Pseudomonas aeruginosa</i> in Jordan: epidemiology, trends, determinants, and clinical outcomes.

Current medical research and opinion·2026
Same journal

RSV disease and vaccination knowledge, attitudes, and practices among US adults: a 2024-2025 RSV season survey.

Current medical research and opinion·2026
Same journal

Clinical and healthcare resource utilization outcomes following revision knee arthroplasty with and without a gradually reducing radius revision knee system.

Current medical research and opinion·2026
Same journal

Medication adherence measurement methods and their reported relationship with medication safety outcomes: a scoping review.

Current medical research and opinion·2026
Same journal

BMI response to dapagliflozin with or without semaglutide across obesity classes: a real-world observational study conducted in Saudi Arabia.

Current medical research and opinion·2026
Same journal

Comparative efficacy of tislelizumab + FOLFOX or CAPOX for gastric/gastroesophageal junction adenocarcinoma: an exploratory matching-adjusted indirect comparison.

Current medical research and opinion·2026
See all related articles

Zolmitriptan effectively treats migraine by targeting the trigeminovascular system. The 2.5 mg dose offers a good balance of efficacy and tolerability, showing superiority over sumatriptan in headache response.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Zolmitriptan is a 5-HT(1B/1D) receptor agonist.
  • It targets the trigeminovascular system for migraine treatment.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of zolmitriptan for migraine.
  • To compare zolmitriptan with sumatriptan.

Main Methods:

  • Dose-ranging studies and direct comparative trials were conducted.
  • Efficacy measured by headache response rates.
  • Adverse events were recorded.

Main Results:

  • Zolmitriptan 2.5 mg demonstrated statistically superior 2-hour headache response compared to sumatriptan 25 and 50 mg.
  • This difference was not clinically significant (3.3%).

Related Experiment Videos

  • No significant difference in adverse event frequency was found between zolmitriptan and sumatriptan.

    • Conclusions:

    • Zolmitriptan 2.5 mg provides a favorable balance of efficacy and tolerability for migraine treatment.
    • It is a viable alternative to sumatriptan with comparable safety profiles.